Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Patients"Success Rate Increases to Record High in 2000: Malpractice Lawsuits
April 23, 2001
- Market Share of Generics Should Be Considered in Pricing of Long-listed Drugs: JMA
April 23, 2001
- LDP's Commission Lists 4 Points of Discussion for NHI Pricing Reform
April 23, 2001
- Mr MRto Enable Physicians to Easily Access Information: Mr Tanimura of So-net M3
April 23, 2001
- REGULATORY NEWS IN BRIEF
April 23, 2001
- MEDICAL DEVICE NEWS IN BRIEF
April 23, 2001
- Marketing of Half-strength Preparations of Digoxin Expected
April 23, 2001
- Quintiles to Double Its Sales in Japan in FY2001
April 16, 2001
- REGULATORY NEWS IN BRIEF -2-
April 16, 2001
- Immediate PMS of Mobic Undertaken by Nippon Boehringer Ingelheim, Daiichi
April 16, 2001
- Bungyo Rate Exceeds 40%for Two Consecutive Months
April 16, 2001
- Developing Anti-AIDS Vaccine to Be Given Top Priority: Merck Company Foundation
April 16, 2001
- Reform of Medical Education Proposed to Promote Patient-centered Healthcare
April 16, 2001
- BUSINESS NEWS IN BRIEF -2-
April 16, 2001
- JPA Starts DispensingError/Incidents Reporting System
April 16, 2001
- Takeda's MRs Supported by Highest Percentage of Physicians
April 16, 2001
- Preventive Effects of Simvastatin on Coronary Events Confirmed: Banyu Symposium
April 16, 2001
- BUSINESS NEWS IN BRIEF -1-
April 16, 2001
- British Gov't Invites Japanese Drug Companies to Invest in UK
April 16, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 16, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…